1. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
- Author
-
Stevens, David A., Schwartz, Howard J., Lee, Jeannette Y., Moskovitz, Bruce L., Jerome, Dennis C., Catanzaro, Antonino, Bamberger, David M., Weinmann, Allison J., Tuazon, Carmelita U., Judson, Marc A., Platts-Mills, Thomas A.E., and DeGraff, Arthur C., Jr.
- Subjects
Aspergillosis -- Drug therapy ,Itraconazole -- Evaluation - Abstract
Patients with allergic bronchopulmonary aspergillosis may benefit from the anti-fungal drug itraconazole. Allergic bronchopulmonary aspergillosis is an infection of the lungs by the fungus Aspergillus fumigatus. Researchers randomly assigned 55 patients with allergic bronchopulmonary aspergillosis to take itraconazole or a placebo every day for 16 weeks. Almost half the patients taking itraconazole experienced an improvement in symptoms and were able to reduce their corticosteroid dose. Only 19% of the placebo group improved. The drug caused no more side effects than the placebo.
- Published
- 2000